Meeting News

Intratumoral therapy increases response to checkpoint inhibitor for melanoma

The phase 2 registration trial designed to evaluate ImmunoPulse IL-12 in combination with pembrolizumab for unresectable metastatic melanoma showed an increase in response rates among patients who were not expected to respond to anti–PD-1 therapy alone.

ImmunoPulse IL-12 (OncoSec Medical) is an intratumoral immunotherapy platform that delivers DNA-based interleukin-12.

Alain Algazi

The single-arm, open-label trial evaluated the combination of ImmunoPulse IL-12 with pembrolizumab (Keytruda, Merck), a PD-1 checkpoint inhibitor, in patients with stage III/IV melanoma who had a low likelihood of responding to an anti–PD-1 therapy based on their tumor biomarkers (CD8–positive tumor infiltrating lymphocytes < 22% PD-1hiCTLA-4+).

Key endpoints included best overall response rate, safety and tolerability, duration of response, 24-week landmark PFS, median PFS and OS.

Patients treated with the combination demonstrated an ORR of 43% at 24 weeks and best ORR of 48%.

In total, 24% of patients achieved complete response, 19% had partial response and 9% demonstrated stable disease, for a total disease control rate of 52%.

The combination demonstrated a favorable safety profile and was well tolerated.

See more from Immuno-Oncology Resource Center